Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing, because here we are — once again — facing the usual growing to-do list of online calls and deadlines and the like. But you know, the world keeps spinning, so time to give it an extra push with a useful cup of stimulation. Our choice this morning is maple bourbon. Yes, this is a real thing. Feel free to join us. Meanwhile, here are a few tidbits to get you going. Hope your day goes delightfully, and do keep in touch. …

The leaders of the world’s wealthiest nations and several drug makers took steps to widen equitable access to Covid-19 vaccines, such as issuing voluntary licenses to expand manufacturing, increasing donations to a global distribution program, and investing in production capacity in Africa, STAT writes. But the Rome Declaration lacked consensus on a proposal supported by the U.S. and dozens of low- and middle-income countries to issue a temporary waiver of intellectual property protections.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.